Teva has launched the generic version of almotriptan malate (Axert), 6.25 mg and 12.5 mg, in the United States.
Teva has launched the generic version of almotriptan malate (Axert), 6.25 mg and 12.5 mg, in the United States. According to the press release, Teva is the first applicant to submit an abbreviated new drug application (ANDA) for almotriptan malate tablets containing a Paragraph IV patent certification.
Paragraph IV certification provides opportunities for generic manufacturers to launch the generic version of a brand drug listed in the orange book before patent expiry. Generics manufacturers are required to certify that patents in the orange book are invalid, unenforceable, and/or the generic drug seeking to be approved will not infringe such patents.
The submission, which was filed on December 7, 2005, is the first ANDA submitted by a generic company containing a Paragraph IV certification for Janssen Pharmaceuticals Axert. Teva is the first applicant to receive approval and will have a period of market exclusivity until the pediatric exclusivity associated with the only patent for Axert expires on November 7, 2015.
Teva has a large portfolio of FDA-approved generic drugs on the market. The company hopes to continue delivering on its generics business strategy. Its focus is to increase first-to-file regulatory submissions in the US.
Axert is marketed by Janssen Pharmaceuticals and recorded annual sales of approximately $31 million in the US, according to March 2015 data from IMS.
Source: Teva
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.